Substituted Azepine Derivatives As Serotonin Receptor Modulators
申请人:Bennani Youssef L.
公开号:US20100190772A1
公开(公告)日:2010-07-29
The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS
申请人:Athersys, Inc.
公开号:EP1778243B1
公开(公告)日:2012-10-31
US7718647B2
申请人:——
公开号:US7718647B2
公开(公告)日:2010-05-18
[EN] SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS<br/>[FR] DERIVES D'AZEPINE SUBSTITUES UTILISES COMME MODULATEURS DES RECEPTEURS DE LA SEROTONINE
申请人:ATHERSYS INC
公开号:WO2006004931A2
公开(公告)日:2006-01-12
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
Substituted azepine derivatives as serotonin receptor modulators
申请人:Bennani L. Youssef
公开号:US20060003990A1
公开(公告)日:2006-01-05
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).